Tailorx: An Update Incl 12-Year Event Rates In Woman With Er+ Lymph Node-Negative Breast Cancer

TAILORx: an update incl 12-year event rates in woman with ER+ lymph node-negative breast cancer

Groundbreaking TAILORx trial results on women with Breast Cancer

Medical Dialogues

Adjuvant Therapy | 2023 Best of Breast Conference

Total Health | Oncology

RxPONDER: sparing chemotherapy in node-positive early-stage breast cancer

What is the prognosis and predictive information for lymph node negative patients?

Breast Cancer Answers®

Omission of Chemotherapy Among Node-Positive Patients With ER+ Breast Cancer

Racial disparities in breast cancer and metastasis and possible contributing biological factors

TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy

Can we decrease chemotherapy in LN+ premenopausal women based on genomic tests?

Oncotype DX Breast Recurrence Score Assay after TAILORx and RxPONDER: What’s Next?

אונקוטסט

What is Node-Positive and Node-Negative Breast Cancer?

Patient Empowerment Network

Genomic predictors for treatment selection in ER+ breast cancer: TAILORx, MINDACT, and RxPONDER

Oncotype DX Testing and the TAILORx Trial

Dr. Hershman on Misconceptions With the TAILORx Trial in HR+/HER2- Breast Cancer

Less Chemotherapy for Breast Cancer: The TAILORx Results

Breast Cancer School for Patients

Dr Richard De Boer discusses the TAILORx trial of OncotypeDX

Breast Cancer Network Australia

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score TAILORx RCT

Surgical Oncology

Advances in breast cancer research make a difference

National Breast Cancer Foundation

Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast Cancer

Total Health | Oncology

Update from the 35th Annual San Antonio Breast Cancer Symposium.

NYU Langone Health